SUPRIYA LIFESCIENCE LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 366.7 INR | -0.23% |
|
-3.66% | +16.51% |
| Sales 2024 * | 5.62B 67.27M | Sales 2025 * | 6.86B 82.21M | Capitalization | 29.51B 353M |
|---|---|---|---|---|---|
| Net income 2024 * | 1.15B 13.75M | Net income 2025 * | 1.5B 17.97M | EV / Sales 2024 * | 5.25 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.3 x |
| P/E ratio 2024 * |
25.6
x | P/E ratio 2025 * |
19.7
x | Employees | 392 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 29.71% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.23% | ||
| 1 week | -3.66% | ||
| Current month | +10.14% | ||
| 1 month | +12.06% | ||
| 3 months | +22.09% | ||
| 6 months | +50.81% | ||
| Current year | +16.51% |
1 week
352.55
373.80
1 month
321.10398.00
Current year
288.90398.00
1 year
215.20398.00
3 years
170.15601.90
5 years
170.15601.90
10 years
170.15601.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 22-10-02 | |
| Director of Finance/CFO | - | 23-01-22 | |
| Chief Operating Officer | - | 04-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 21-03-24 | |
| Director/Board Member | 65 | 21-03-24 | |
| Founder | 68 | 08-03-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 366.7 | -0.23% | 115,983 |
| 24-04-16 | 367.6 | +1.09% | 142,995 |
| 24-04-15 | 363.6 | -2.64% | 235,000 |
| 24-04-12 | 373.4 | -1.89% | 143,072 |
| 24-04-10 | 380.6 | +0.66% | 180,806 |
End-of-day quote NSE India S.E., April 17, 2024
More quotes
Supriya Lifescience Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs). The Company is primarily engaged in manufacturing of bulk drugs and pharmaceutical chemicals. The Company exports its products in the antihistamine, anesthetics and anti-asthma therapy categories to approximately 86 countries. The Company's product portfolio consists of approximately 38 niche API products that address remedies in therapeutic segments, such as antihistamine, analgesic, vitamin, anesthetics and anti-asthmatics, among others. The Company has manufacturing facilities located in Maharashtra. Its products include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others.
Sector
Pharmaceuticals
Calendar
2024-05-16
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +16.51% | 353M | |
| +27.97% | 672B | |
| +23.45% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.30% | 211B | |
| -0.72% | 203B | |
| -10.35% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- SUPRIYA Stock
